Abstract
Acute myeloid leukemia (AML) diagnosis is increasingly based on the underlying genetic characteristics. While conventional cytogenetic analysis still comprises the backbone of AML classification, evaluation of several gene mutations is now becoming standard of care for diagnosis, prognostic stratification, and differentially tailored treatment strategies. Genomic technologies have rapidly increased our understanding of the molecular pathogenesis of AML, and this new information is being actively evaluated in comprehensive mutation panels with promise to further improve patient outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
